**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 88877

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Silencing of Jumonji domain-containing 1C inhibits the osteogenic differentiation of bone marrow mesenchymal stem cells *via* nuclear factor-κB signaling**

Li JY *et al*. JMJD1C regulate osteogenic differentiation of BMSCs

Jing-Yi Li, Ting-Ting Wang, Li Ma, Yu Zhang, Di Zhu

**Jing-Yi Li,** Department of Medical Cosmetology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

**Ting-Ting Wang,** Department of General Gerontology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Li Ma,** Department of Plastic Surgery, China-Japan Friendship Hospital, Beijing 100029, China

**Yu Zhang,** Senior Department of Hematology, The Fifth Medical Centre, General Hospital of Chinese People’s Liberation Army, Beijing 100071, China

**Di Zhu,** Department of Orthopaedic Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

**Author contributions:** Li JY contributed independently to this work, and performed most of the research; Li JY, Wang TT, Ma L, Zhang Y, and Zhu D designed the research study; Li JY, Wang TT, Ma L, and Zhang Y contributed new reagents and analytic tools, analyzed the data and wrote and revised the manuscript; and all authors have read and approve the final manuscript.

**Supported by** 2018 Henan Medical Science and Technology Research Plan Project, China, No. SBGJ2018019.

**Corresponding author: Di Zhu, MD, Academic Research,** Department of Orthopaedic Surgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing 100070, China. zhudi214@126.com

**Received:** November 5, 2023

**Revised:** December 20, 2023

**Accepted:** January 17, 2024

**Published online:** February 26, 2024

**Abstract**

BACKGROUND

Osteoporosis is a common metabolic bone disorder induced by an imbalance between osteoclastic activity and osteogenic activity. During osteoporosis, bone mesenchymal stem cells (BMSCs) exhibit an increased ability to differentiate into adipocytes and a decreased ability to differentiate into osteoblasts, resulting in bone loss. Jumonji domain-containing 1C (*JMJD1C*) has been demonstrated to suppress osteoclastogenesis.

AIM

To examine the effect of *JMJD1C* on the osteogenesis of BMSCs and the potential underlying mechanism.

METHODS

BMSCs were isolated from mouse bone marrow tissues. Oil Red O staining, Alizarin red staining, alkaline phosphatase staining and the expression of adipogenic and osteogenic-associated genes were assessed to determine the differentiation of BMSCs. Bone marrow-derived macrophages (BMMs) were incubated with receptor activator of nuclear factor-kappa Β ligand to induce osteoclast differentiation, and osteoclast differentiation was confirmed by tartrate-resistant acid phosphatase staining. Other related genes were measured *via* reverse transcription coupled to the quantitative polymerase chain reaction and western blotting. Enzyme-linked immunosorbent assays were used to measure the levels of inflammatory cytokines, including tumor necrosis factor alpha, interleukin-6 and interleukin-1 beta.

RESULTS

The osteogenic and adipogenic differentiation potential of BMSCs isolated from mouse bone marrow samples was evaluated. *JMJD1C* mRNA and protein expression was upregulated in BMSCs after osteoblast induction, while p-nuclear factor-κB (NF-κB) and inflammatory cytokines were not significantly altered. Knockdown of *JMJD1C* repressed osteogenic differentiation and enhanced NF-κB activation and inflammatory cytokine release in BMSCs. Moreover, *JMJD1C* expression decreased during BMM osteoclast differentiation.

CONCLUSION

The *JMJD1C*/NF-κB signaling pathway is potentially involved in BMSC osteogenic differentiation and may play vital roles in the pathogenesis of osteoporosis.

**Key Words:** Osteoporosis; Mesenchymal stem cells; Osteogenesis; Jumonji domain-containing 1C; Nuclear factor-κB

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Li JY, Wang TT, Ma L, Zhang Y, Zhu D. Silencing of Jumonji domain-containing 1C inhibits the osteogenic differentiation of bone marrow mesenchymal stem cells *via* nuclear factor-κB signaling. *World J Stem Cells* 2024; 16(2): 151-162

**URL**: https://www.wjgnet.com/1948-0210/full/v16/i2/151.htm

**DOI**: https://dx.doi.org/10.4252/wjsc.v16.i2.151

**Core Tip:** Jumonji domain-containing 1C (*JMJD1C*) is a marker gene for osteoporosis disease. *JMJD1C* promotes osteogenic differentiation of bone mesenchymal stem cells (BMSCs). *JMJD1C* inhibited osteoclast differentiation of bone marrow-derived macrophages. *JMJD1C* knockdown promotes nuclear factor-κB activation in BMSCs during osteogenic differentiation.

**INTRODUCTION**

Osteoporosis is a common bone disease worldwide characterized by low bone mineral density that can cause fractures in affected bones[1]. This condition is prevalent among elderly individuals, particularly women of postmenopausal age[2]. Osteoporosis is elicited by the disequilibrium of osteoblastic bone formation and osteoclastic bone resorption[3]. Current therapies for osteoporosis mainly focus on the regulation of bone remodeling; nevertheless, these treatments have certain adverse effects and limitations[4]. Further elucidation of the molecular mechanisms underlying osteoporosis is important for developing effective therapeutic strategies for this disease.

Bone mesenchymal stem cells (BMSCs), progenitor cells that can be isolated from bone marrow, can differentiate into various types of cells, such as adipocytes and osteoblasts[5]. As the progenitor cells of adipocytes and osteoblasts, BMSCs play a critical role in bone homeostasis[6]. Recent methods and current developments in utilizing BMSCs for the repair of bone fractures resulting from osteoporosis have been reported in many studies[7]. Moreover, previous studies have reported that osteoporotic BMSCs exhibit impaired osteogenic differentiation potential[8-10].

Jumonji domain-containing (JMJD) proteins, which have histone lysine demethylase (KDM) activities, constitute a large protein family with more than 30 members[11]. One subfamily of JMJD proteins comprises *KDM3A/JMJD1A*, *KDM3B/JMJD1B* and *KDM3C/JMJD1C*[12]. In oral inflammatory lesions, JMJD1C deficiency results in elevated alveolar bone loss. Moreover, loss of *JMJD1C* accelerates bone marrow-derived macrophage (BMM) differentiation into osteoclasts *in vitro*[13]. Database analysis revealed that *JMJD1C* expression is downregulated in bone marrow stromal cells (BMSCs) from patients with osteoporosis. *JMJD1C* levels are upregulated in osteogenic induction medium and BMSC growth medium supplemented with modified extracellular matrix[14]. However, whether *JMJD1C* is involved in osteoblast differentiation of BMSCs during osteoporosis is still unclear.

Nuclear factor-κB (NF-κB) is a transcription factor that modulates the expression of many genes implicated in the immune response and inflammation[15]. Previous findings also revealed that NF-κB is an essential factor that contributes to impaired bone formation during osteoporosis[16]. Moreover, NF-κB suppression improved osteopenia and promoted bone formation in a mouse model of osteoporosis[17]. Moreover, repression of the NF-κB pathway induces osteogenic differentiation in MSCs[18]. Importantly, complete knockout and transient knockdown of *JMJD1C* led to the activation of the NF-κB subunit p65 in both mouse and human macrophages[13].

Here, this study explored the role of *JMJD1C* in BMSC osteogenic differentiation and the potential underlying mechanisms. We demonstrated that *JMJD1C* expression was increased while NF-κB signaling activation was not affected during BMSC osteogenic differentiation. Silencing of *JMJD1C* suppressed osteogenic differentiation and promoted NF-κB activation in BMSCs. Therefore, this study might lead to the identification of an innovative target for treating osteoporosis.

**MATERIALS AND METHODS**

***Cell culture***

C57BL/6 mice (8 wk old) obtained from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., were housed in pathogen-free facilities under a light/dark cycle of 12/12 h. The animal experiments were approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated with Capital Medical University. Primary BMSCs were isolated as described previously. In brief, after anesthesia, the mice were sacrificed *via* cervical dislocation. Bone marrow cells were collected from the tibiae and femurs of the mice. The cells were maintained in α-MEM (Gibco, Grand Island, NY, United States) supplemented with 1% penicillin/streptomycin (Gibco) and 10% fetal bovine serum (FBS) (Gibco) in an incubator with 5% CO2 at 37 °C. When the cells reached 80% confluence, they were digested and cultured. Cells (5-9 passages) were collected for the next assays. BMMs from mice were cultured in α-MEM supplemented with macrophage colony-stimulating factor (M-CSF, 5 ng/mL), 1% penicillin/streptomycin and 10% FBS. The BMSCs were randomly divided into five groups: Control (without any treatment), osteoblast induction (maintained in osteogenic induction medium for the indicated time periods), adipocyte induction (cultured in adipogenic induction medium for 14 d), short hairpin RNAs (shRNAs)-NC (transfected with shRNA-NC for 48 h) and shRNA*-JMJD1C* (transfected with shRNA-*JMJD1C* for 48 h). In addition, the BMMs were randomly divided into two groups: Control (BMMs without any treatment) and osteoclast induction [BMMs treated with receptor activator of nuclear factor-kappa Β ligand (RANKL) for 7 d] groups.

***Flow cytometry***

BMSC surface markers were detected *via* flow cytometry. Briefly, after being rinsed by phosphate buffered saline (PBS), the BMSCs were collected with trypsin. After centrifugation at 1500 rpm, the cells were incubated for 0.5 h with primary antibodies against CD29, CD31, CD34, CD45, CD90, MHCII, SCA-1 and CD11b (Biolegend, California, San Diego, United States and Becton Dickinson, Franklin Lakes, NJ, United States). Afterward, flow cytometry (Becton Dickinson, Franklin Lakes, NJ, United States) was used to assess the cells.

***Osteoblast differentiation***

BMSCs were maintained in osteogenic induction medium (α-MEM supplemented with 10-7 M dexamethasone, 10 mmol/L β-glycerophosphate, 0.2 mmol/L ascorbic acid, 1% penicillin/streptomycin and 10% FBS) to induce osteogenic differentiation. The osteogenic induction medium was replaced every 3 d.

***Alkaline phosphatase staining***

In accordance with the manufacturer’s instructions, alkaline phosphatase (ALP) staining of cells was performed using a BCIP/NBT ALP color development kit (Beyotime, Jiangsu, China) following 7 d of osteogenic induction. Briefly, after rinsing with PBS, the BMSCs were fixed in paraformaldehyde (4%). Afterward, the cells were treated with BCIP/NBT staining solution. The color development reaction was terminated using deionized water. A light microscope (Olympus, Tokyo, Japan) was used to observe the results.

***Alizarin red staining***

According to the manufacturer’s protocol, osteogenic differentiation was evaluated by Alizarin red staining following osteogenic induction for 21 d. In brief, the cells were washed with PBS. After fixation with paraformaldehyde (4%), 500 μL of Alizarin red staining solution was added to the cells (1%, Sigma, St. Louis, MO, United States). Fifteen minutes later, the staining solution was discarded. A light microscope (Olympus) was used to observe the results after the cells were washed three times with PBS.

***Adipogenic differentiation***

For induction of adipogenic differentiation, BMSCs (2.5 × 106 cells per well) were cultured for 14 d in 6-well plates with adipogenic induction medium (1 μmol/L dexamethasone, 0.5 mmol/L 3-isobutyl-1-methylxanthine, 5 μg/mL insulin, and 10% FCS in α-MEM). The culture medium was changed every other day.

***Oil red O staining***

After adipogenesis induction for 14 d, mature adipocytes were distinguished from preadipocytes using Oil Red O staining. In brief, after rinsing with PBS, the cells were fixed in paraformaldehyde (4%) at room temperature for 30 min. The cells were then washed with PBS and stained with Oil Red O. Twenty minutes later, a light microscope (Olympus) was used to observe the cells.

***Osteoclast differentiation***

For osteoclast differentiation, 10 ng/mL RANKL obtained from R&D Systems (Minneapolis, MN, United States) was used to treat the BMMs for 7 d.

***Tissue-resistant acid phosphatase staining***

Osteoclast differentiation of BMMs was confirmed by using tissue-resistant acid phosphatase (TRAP) staining. In brief, the cells were fixed in paraformaldehyde (4%). TRAP staining was performed instantly in the dark for 30 min at 37 °C. The images were obtained by using an optical microscope (Olympus). TRAP-positive cells containing at least 3 nuclei were regarded as osteoclasts.

***Cell transfection***

A lentivirus containing short hairpin RNA against *JMJD1C* (sh-*JMJD1C*) was obtained from Sangon Biotech (Shanghai, China) for *JMJD1C* knockdown in BMSCs, and the lentivirus was used to transfect the cells following the manufacturer’s instructions for viral infection. The cells were collected for subsequent assays after 48 h of transfection.

***Reverse transcription coupled to the quantitative polymerase chain reaction***

TRIzol (Invitrogen, Carlsbad, CA, United States) was used to extract total RNA. A PrimeScript RT reagent kit (TaKaRa, Tokyo, Japan) was used to transcribe the extracted RNA into cDNA. A CFX96™ Real Time RT-PCR System was used for analysis with SYBR Premix Ex Taq™ II (TaKaRa). Glyceraldehyde 3-phosphate dehydrogenase was used for normalization. The synthesized primers are shown in Table 1. The relative gene expression levels were analyzed with the 2-ΔΔCT method.

***Western blot***

RIPA buffer (Thermo Fisher Scientific) with protease and phosphatase inhibitors was used for extraction of total protein at 4 °C for 0.5 h. A BCA protein assay reagent kit (Thermo Fisher Scientific) was used to determine the protein concentrations in the cell lysates. Next, the protein samples were separated *via* 10% sodium-dodecyl sulfate gel electrophoresis (Bio-Rad, Hercules, CA, United States) before being transferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA, United States). Five percent BSA was used to block the membranes at room temperature for 1 h. Then, the membranes were incubated at 4 °C overnight with primary antibodies against JMJD1C (Invitrogen), p-NF-κB (Abcam), NF-κB (Abcam) and β-tubulin (Abcam). Next, the sections were incubated with secondary antibodies. Ultimately, enhanced chemiluminescence reagent (Beyotime) was used to detect the immunoreactive bands. Image Lab (Bio-Rad, Hercules, CA, United States) was used to quantify the band intensity.

***Enzyme-linked immunosorbent assay***

In accordance with the manufacturer’s instructions, enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, United States) were used to measure the levels of cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and IL-1β, in the supernatants. A microplate reader was used to determine the absorbance value of each sample.

***Statistical analysis***

The data of this study were accessed by GraphPad Prism 8.0 software. Analysis of variance (ANOVA) or Student’s *t* test was used to analyze the results. *P* < 0.05 was regarded as significant, and the outcomes are presented as the means ± SD.

**RESULTS**

***Osteogenic and adipogenic differentiation of BMSCs***

First, we separated BMSCs from mouse bone marrow tissues. Flow cytometry was conducted to identify the BMSCs. As displayed in Figure 1A, BMSCs highly expressed specific stem cell markers, including CD29, CD90 and SCA-1 but weakly expressed CD31, CD45, CD34, MHC2 and CD11b. The results indicated that the BMSCs were successfully separated from the mouse bone marrow. Osteogenic differentiation of BMSCs was induced by incubating the cells with osteogenic induction medium. ALP staining revealed a high level of ALP in BMSCs on day 14 (Figure 1B). Alizarin red staining revealed calcium deposition in the BMSCs on day 21 (Figure 1C). The expression of several osteogenesis-related genes, including Osteocalin, Runt-related transcription factor 2 and ALP, increased after osteogenic induction (Figure 1D). These data suggested successful osteogenic differentiation. Next, the BMSCs were maintained in adipogenic induction medium. The results from Oil Red O staining revealed various lipid drops within the differentiated cells after 14 d of adipogenic differentiation (Figure 1E). In addition, the expression of adipogenesis-related genes, including peroxisome proliferator-activated receptor gamma and CCAAT enhancer-binding protein alpha, was significantly increased in BMSCs after adipocyte induction (Figure 1F). These results indicated successful adipogenic differentiation of BMSCs.

***JMJD1C was upregulated but NF-κB activation was not affected during the osteogenic differentiation of BMSCs***

To determine the role of *JMJD1C* in BMSC osteogenic differentiation, we induced osteogenic differentiation in BMSCs. The reverse transcription coupled to the quantitative polymerase chain reaction results revealed that *JMJD1C* mRNA expression was significantly increased in BMSCs after osteoblast induction (Figure 2A). Consistently, the *JMJD1C* protein level was increased after osteoblast induction, as shown by western blotanalysis (Figure 2B and C). These data indicated that *JMJD1C* was upregulated during BMSC osteogenic differentiation. In addition, the protein expression of p-NF-κB was not significantly altered in BMSCs after osteoblast induction (Figure 2B and D). Moreover, the cytokine secretion levels of IL-1β, IL-6 and TNF-α were not significantly altered in BMSCs after osteoblast induction (Figure 2E-G).

***JMJD1C knockdown inhibited osteogenic differentiation and promoted******NF-κB activation in BMSCs***

To further explore the role of *JMJD1C* in BMSC osteogenesis, we knocked down *JMJD1C* in BMSCs by infection with a lentivirus harboring sh-JMJD1C. Compared with that in the control group, the *JMJD1C* protein level was notably lower in the cells transfected with shRNA-*JMJD1C* (Figure 3A and B), indicating successful knockdown of *JMJD1C*. Depletion of *JMJD1C* notably upregulated the protein expression of p-NF-κB (Figure 3A and C), which indicated that *JMJD1C* knockdown facilitated NF-κB activation in BMSCs. Moreover, knocking down *JMJD1C* inhibited stem cell osteogenic differentiation (Figure 3D and E). Moreover, the secretion of the cytokines IL-1β, IL-6 and TNF-α was significantly increased (Figure 3F-H). These findings indicated that *JMJD1C* promotes cell osteogenic differentiation by negatively regulating p-NF-κB expression in BMSCs.

***JMJD1C was downregulated during RANKL-induced osteoclast differentiation in BMMs***

Osteoclast differentiation was induced in BMMs by treatment with RANKL and M-CSF. The number of TRAP+ multinucleated osteoclasts was significantly greater after 7 d of stimulation than that in the control group, as shown by TRAP staining (Figure 4A), which indicated successful osteoclast differentiation of BMMs induced by RANKL and M-CSF. Compared with those in the control group, *JMJD1C* mRNA and protein levels were notably lower in cells undergoing osteoclast differentiation (Figure 4B-D). Taken together, these data suggested that *JMJD1C* was downregulated during BMM osteoclast differentiation.

**DISCUSSION**

Osteoporosis is a common bone disorder that arises from an imbalance in bone homeostasis[19]. Impaired BMSC osteogenesis, decreased bone formation and increased marrow adiposity were observed in osteoporosis[20]. Herein, BMSCs isolated from the bone marrow of mice were characterized for their ability to differentiate into osteoblasts and adipocytes. *JMJD1C* was increased while NF-κB activation was not altered in BMSCs during osteogenic differentiation. Moreover, *JMJD1C* depletion suppressed osteogenic differentiation and facilitated the activation of NF-κB signaling in BMSCs.

During osteoporosis development, BMSCs exhibit an increased ability to differentiate into adipocytes and a decreased capability to differentiate into osteoblasts, leading to an increase in fat accumulation and a decrease in bone formation[21]. An imbalance in BMSC differentiation has been demonstrated to be a critical mechanism underlying osteoporosis pathogenesis. For example, transcriptionally regulating BMSC differentiation by DEPTOR exacerbates the imbalance of bone fat in osteoporosis[22]. In age-related osteoporosis, the adipogenic differentiation of BMSCs is suppressed, and the osteoblastic differentiation of BMSCs is promoted by the overexpression of miR-130a[23]. The promoted BMSC osteogenesis induced by Foxf1 knockdown contributes to the prevention of ovariectomy-elicited bone loss[24]. Investigating the molecular mechanism modulating adipogenic differentiation and osteogenic differentiation in BMSCs is critical for comprehending the development of osteoporosis and identifying innovative treatment approaches. In the present study, BMSCs cultured in osteogenic induction medium exhibited obvious calcium deposition and osteogenic differentiation, which was in line with the findings of previous studies.

Recent studies on *JMJD1C* have focused predominantly on tumors and cancers[25,26]. In addition, *JMJD1C* is involved in regulating cell differentiation in many cells. For example, *JMJD1C* knockdown is sufficient to trigger neural differentiation of human embryonic stem cells[27]; *JMJD1C* silencing leads to the induction of differentiation of mouse embryonic stem cells[28]. However, whether *JMJD1C* is closely associated with osteogenic differentiation is still unclear. A previous study confirmed that in murine 3T3-L1 preadipocyte cells, knockdown of JMJD1C can impair adipogenesis[29]. BMMs isolated from *JMJD1C* knockout mice exhibit enhanced osteoclastogenesis[13]. Furthermore, *KDM3B/JMJD1B* has been identified as a potential modulator of osteogenic differentiation[30]. Herein, this study revealed that *JMJD1C* mRNA and protein levels were elevated during the osteogenic differentiation of BMSCs. In addition, *JMJD1C* expression decreased in BMMs after osteoclast differentiation. Moreover, we found that *JMJD1C* knockdown suppressed BMSC osteogenic differentiation. Our study demonstrated the involvement of *JMJD1C* in regulating BMSC osteogenesis.

NF-κB, an essential transcription factor, is implicated in numerous cellular pathophysiological activities. Moreover, many studies have revealed that NF-κB signaling plays a vital role in osteoblast differentiation. For example, taxifolin promotes BMSC osteogenic differentiation partially through the NF-κB pathway[31]. Melatonin alleviates inflammation and facilitates osteoblast differentiation of BMSCs by repressing the NF-κB pathway[32]. Moreover, in BMSCs from systemic lupus erythematosus patients, activated NF-κB suppressed osteogenic differentiation through downregulation of Smad signaling[33]. TRIM38 acts as a negative modulator of NF-κB during the differentiation of osteoblasts, playing an essential role in bone remodeling[34]. Taken together, these findings suggest that NF-κB may play an essential role in osteoporosis development. Here, we discovered that p-NF-κB expression and inflammatory cytokines, including TNF-α, IL-6 and IL-1β, were not altered in BMSCs during osteogenic differentiation.

Recent studies have revealed the involvement of the NF‑κB pathway in the functional roles of JMJD proteins in various pathological processes. JMJD3 was found to regulate osteoclastogenesis *via* RANKL and Ephrin receptor B4 signaling[35]. Inhibition of *JMJD1A/KDM3A* ameliorates hyperglycemia-mediated myocardial injury by modulating NF-κB/p65[36]. *JMJD1A/KDM3A* gene silencing mitigates the phosphorylation of MAPKs and NF-κB/p65 activation to attenuate vascular smooth muscle cell injury[37]. Furthermore, in mouse BMMs, *JMJD1C* silencing promoted NF-κB activation and translocation and resulted in enhanced secretion of IL-6, IL-1β and TNF-α[13]. Similarly, in the present study, JMJD1C knockdown in BMSCs upregulated p-NF-κB expression. Thus, our findings further confirm the negative regulatory effect of *JMJD1C* on the expression of p-NF-κB. Moreover, *JMJD1C* knockdown promoted the release of inflammatory cytokines (IL-6, IL-1β, and TNF-α) in BMSCs. Additionally, *JMJD1C* knockdown suppressed BMSC osteogenic differentiation. Taken together, our study suggested that JMJD1C may play a role through the NF-κB pathway during the osteogenic differentiation of BMSCs. However, the role of *JMJD1C*/NF-κB signaling in BMSC osteogenic differentiation requires further exploration.

**CONCLUSION**

In conclusion, during osteogenic differentiation, *JMJD1C* was upregulated, while NF-κB activation was not altered in BMSCs. *JMJD1C* knockdown inhibited osteogenic differentiation and enhanced the activation of NF-κB signaling in BMSCs. Therefore, the *JMJD1C*/NF-κB pathway may modulate the osteoblast differentiation of BMSCs, which is possibly involved in the pathogenesis of osteoporosis.

**ARTICLE HIGHLIGHTS**

***Research background***

Osteoporosis, particularly women of postmenopausal age is elicited by the disequilibrium of osteoblastic bone formation and osteoclastic bone resorption. Elucidation of the molecular mechanisms underlying osteoporosis is important for developing effective therapeutic strategies for this disease.

***Research motivation***

Bone mesenchymal stem cells (BMSCs) have certain characteristics of differentiation into various types of cells, such as adipocytes and osteoblasts. So that, BMSCs are playing a critical role in bone homeostasis and munch more research groups are utilizing BMSCs for the repair of bone fractures resulting from osteoporosis. The researchers found that Jumonji C domain-containing 1C (*JMJD1C*) deficiency results in elevated alveolar bone loss in oral inflammatory lesions and loss of *JMJD1C* accelerates bone marrow-derived macrophage (BMM) differentiation into osteoclasts *in vitro*. Database analysis revealed that *JMJD1C* expression is downregulated in BMSCs from patients with osteoporosis. Furthermore, researchers revealed that *JMJD1C* levels are increased in osteogenic induction medium and BMSC growth medium supplemented with modified extracellular matrix.

***Research objectives***

To investigate whether *JMJD1C* is involved in osteoblast differentiation of BMSCs during osteoporosis.

***Research methods***

We isolated BMSCs from C57/BL6 suckling mice bone marrow tissues. We assessed the differentiation of BMSCs with Oil Red O staining, Alizarin red staining, alkaline phosphatase staining and reverse transcription coupled to the quantitative polymerase chain reaction. We isolated BMMs and incubated with receptor activator of nuclear factor-kappa Β ligand to induce osteoclast differentiation. The tartrate-resistant acid phosphatase staining were used to confirm the effect of osteoclast differentiation. We used enzyme-linked immunosorbent assay to measure the levels of inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL)-6 and IL-1β.

***Research results***

*JMJD1C* mRNA and protein expression was increased in BMSCs after osteoblast induction. Silence *JMJD1C* repressed osteogenic differentiation and enhanced nuclear factor-κB (NF-κB) activation and inflammatory cytokine release in BMSCs. *JMJD1C* upregulation decreased during BMM osteoclast differentiation.

***Research conclusions***

We found that the signaling pathway of *JMJD1C*/NF-κB is potentially involved in BMSC osteogenic differentiation and may play vital roles in the pathogenesis of osteoporosis.

***Research perspectives***

R&D of MSCs (BMSC, adipose-derived SC, human umbilical cord MSC and embryonic SC, *etc.*) and their preparations in the field of osteoporosis treatment.

**REFERENCES**

1 **Song S**, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis. *Pharmacol Ther* 2022; **237**: 108168 [PMID: 35283172 DOI: 10.1016/j.pharmthera.2022.108168]

2 **Zhang L**, Zheng YL, Wang R, Wang XQ, Zhang H. Exercise for osteoporosis: A literature review of pathology and mechanism. *Front Immunol* 2022; **13**: 1005665 [PMID: 36164342 DOI: 10.3389/fimmu.2022.1005665]

3 **Aibar-Almazán A**, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF, Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of Osteoporosis. *Int J Mol Sci* 2022; **23** [PMID: 36012730 DOI: 10.3390/ijms23169465]

4 **Liang B**, Burley G, Lin S, Shi YC. Osteoporosis pathogenesis and treatment: existing and emerging avenues. *Cell Mol Biol Lett* 2022; **27**: 72 [PMID: 36058940 DOI: 10.1186/s11658-022-00371-3]

5 **Guo Q**, Guo Q, Xiao Y, Li C, Huang Y, Luo X. Regulation of bone marrow mesenchymal stem cell fate by long non-coding RNA. *Bone* 2020; **141**: 115617 [PMID: 32853852 DOI: 10.1016/j.bone.2020.115617]

6 **Ning K**, Liu S, Yang B, Wang R, Man G, Wang DE, Xu H. Update on the effects of energy metabolism in bone marrow mesenchymal stem cells differentiation. *Mol Metab* 2022; **58**: 101450 [PMID: 35121170 DOI: 10.1016/j.molmet.2022.101450]

7 **Arthur A**, Gronthos S. Clinical Application of Bone Marrow Mesenchymal Stem/Stromal Cells to Repair Skeletal Tissue. *Int J Mol Sci* 2020; **21** [PMID: 33371306 DOI: 10.3390/ijms21249759]

8 **Bidwell JP**, Alvarez MB, Hood M Jr, Childress P. Functional impairment of bone formation in the pathogenesis of osteoporosis: the bone marrow regenerative competence. *Curr Osteoporos Rep* 2013; **11**: 117-125 [PMID: 23471774 DOI: 10.1007/s11914-013-0139-2]

9 **Li D**, Yuan Q, Xiong L, Li A, Xia Y. The miR-4739/DLX3 Axis Modulates Bone Marrow-Derived Mesenchymal Stem Cell (BMSC) Osteogenesis Affecting Osteoporosis Progression. *Front Endocrinol (Lausanne)* 2021; **12**: 703167 [PMID: 34925225 DOI: 10.3389/fendo.2021.703167]

10 **Li H**, Liu P, Xu S, Li Y, Dekker JD, Li B, Fan Y, Zhang Z, Hong Y, Yang G, Tang T, Ren Y, Tucker HO, Yao Z, Guo X. FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. *J Clin Invest* 2017; **127**: 1241-1253 [PMID: 28240601 DOI: 10.1172/JCI89511]

11 **Manni W**, Jianxin X, Weiqi H, Siyuan C, Huashan S. JMJD family proteins in cancer and inflammation. *Signal Transduct Target Ther* 2022; **7**: 304 [PMID: 36050314 DOI: 10.1038/s41392-022-01145-1]

12 **Sui Y**, Gu R, Janknecht R. Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer. *Mol Cancer Res* 2021; **19**: 3-13 [PMID: 32605929 DOI: 10.1158/1541-7786.MCR-20-0404]

13 **Lee JY**, Mehrazarin S, Alshaikh A, Kim S, Chen W, Lux R, Gwack Y, Kim RH, Kang MK. Histone Lys demethylase KDM3C demonstrates anti-inflammatory effects by suppressing NF-κB signaling and osteoclastogenesis. *FASEB J* 2019; **33**: 10515-10527 [PMID: 31251083 DOI: 10.1096/fj.201900154RR]

14 **Liu H**, Yang L, Zhang E, Zhang R, Cai D, Zhu S, Ran J, Bunpetch V, Cai Y, Heng BC, Hu Y, Dai X, Chen X, Ouyang H. Biomimetic tendon extracellular matrix composite gradient scaffold enhances ligament-to-bone junction reconstruction. *Acta Biomater* 2017; **56**: 129-140 [PMID: 28502669 DOI: 10.1016/j.actbio.2017.05.027]

15 **Jimi E**, Takakura N, Hiura F, Nakamura I, Hirata-Tsuchiya S. The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition "Killing Two Birds with One Stone"? *Cells* 2019; **8** [PMID: 31847314 DOI: 10.3390/cells8121636]

16 **Chang J**, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. *Nat Med* 2009; **15**: 682-689 [PMID: 19448637 DOI: 10.1038/nm.1954]

17 **Alles N**, Soysa NS, Hayashi J, Khan M, Shimoda A, Shimokawa H, Ritzeler O, Akiyoshi K, Aoki K, Ohya K. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice. *Endocrinology* 2010; **151**: 4626-4634 [PMID: 20810563 DOI: 10.1210/en.2010-0399]

18 **Chen X**, Liu Y, Ding W, Shi J, Li S, Liu Y, Wu M, Wang H. Mechanical stretch-induced osteogenic differentiation of human jaw bone marrow mesenchymal stem cells (hJBMMSCs) via inhibition of the NF-κB pathway. *Cell Death Dis* 2018; **9**: 207 [PMID: 29434225 DOI: 10.1038/s41419-018-0279-5]

19 **Li Z**, Li D, Chen R, Gao S, Xu Z, Li N. Cell death regulation: A new way for natural products to treat osteoporosis. *Pharmacol Res* 2023; **187**: 106635 [PMID: 36581167 DOI: 10.1016/j.phrs.2022.106635]

20 **Pierce JL**, Begun DL, Westendorf JJ, McGee-Lawrence ME. Defining osteoblast and adipocyte lineages in the bone marrow. *Bone* 2019; **118**: 2-7 [PMID: 29782940 DOI: 10.1016/j.bone.2018.05.019]

21 **Hu L**, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. *Int J Mol Sci* 2018; **19** [PMID: 29370110 DOI: 10.3390/ijms19020360]

22 **Ouyang Z**, Kang D, Li K, Liang G, Liu Z, Mai Q, Chen Q, Yao C, Wei R, Tan X, Bai X, Huang B, Li Q. DEPTOR exacerbates bone-fat imbalance in osteoporosis by transcriptionally modulating BMSC differentiation. *Biomed Pharmacother* 2022; **151**: 113164 [PMID: 35609371 DOI: 10.1016/j.biopha.2022.113164]

23 **Lin Z**, He H, Wang M, Liang J. MicroRNA-130a controls bone marrow mesenchymal stem cell differentiation towards the osteoblastic and adipogenic fate. *Cell Prolif* 2019; **52**: e12688 [PMID: 31557368 DOI: 10.1111/cpr.12688]

24 **Shen G**, Ren H, Shang Q, Zhao W, Zhang Z, Yu X, Tang K, Tang J, Yang Z, Liang D, Jiang X. Foxf1 knockdown promotes BMSC osteogenesis in part by activating the Wnt/β-catenin signalling pathway and prevents ovariectomy-induced bone loss. *EBioMedicine* 2020; **52**: 102626 [PMID: 31981979 DOI: 10.1016/j.ebiom.2020.102626]

25 **Zhong C**, Tao B, Yang F, Xia K, Yang X, Chen L, Peng T, Xia X, Li X, Peng L. Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a. *Clin Transl Med* 2021; **11**: e424 [PMID: 34586733 DOI: 10.1002/ctm2.424]

26 **Lynch JR**, Salik B, Connerty P, Vick B, Leung H, Pijning A, Jeremias I, Spiekermann K, Trahair T, Liu T, Haber M, Norris MD, Woo AJ, Hogg P, Wang J, Wang JY. JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. *Leukemia* 2019; **33**: 1400-1410 [PMID: 30622285 DOI: 10.1038/s41375-018-0354-z]

27 **Wang J**, Park JW, Drissi H, Wang X, Xu RH. Epigenetic regulation of miR-302 by JMJD1C inhibits neural differentiation of human embryonic stem cells. *J Biol Chem* 2014; **289**: 2384-2395 [PMID: 24318875 DOI: 10.1074/jbc.M113.535799]

28 **Xiao F**, Liao B, Hu J, Li S, Zhao H, Sun M, Gu J, Jin Y. JMJD1C Ensures Mouse Embryonic Stem Cell Self-Renewal and Somatic Cell Reprogramming through Controlling MicroRNA Expression. *Stem Cell Reports* 2017; **9**: 927-942 [PMID: 28826851 DOI: 10.1016/j.stemcr.2017.07.013]

29 **Buerger F**, Müller S, Ney N, Weiner J, Heiker JT, Kallendrusch S, Kovacs P, Schleinitz D, Thiery J, Stadler SC, Burkhardt R. Depletion of Jmjd1c impairs adipogenesis in murine 3T3-L1 cells. *Biochim Biophys Acta Mol Basis Dis* 2017; **1863**: 1709-1717 [PMID: 28501567 DOI: 10.1016/j.bbadis.2017.05.011]

30 **Munehira Y**, Yang Z, Gozani O. Systematic Analysis of Known and Candidate Lysine Demethylases in the Regulation of Myoblast Differentiation. *J Mol Biol* 2017; **429**: 2055-2065 [PMID: 27732873 DOI: 10.1016/j.jmb.2016.10.004]

31 **Wang YJ**, Zhang HQ, Han HL, Zou YY, Gao QL, Yang GT. Taxifolin enhances osteogenic differentiation of human bone marrow mesenchymal stem cells partially via NF-κB pathway. *Biochem Biophys Res Commun* 2017; **490**: 36-43 [PMID: 28579433 DOI: 10.1016/j.bbrc.2017.06.002]

32 **Hu Y**, Xiong Y, Zha K, Tao R, Chen L, Xue H, Yan C, Lin Z, Endo Y, Cao F, Zhou W, Liu G. Melatonin Promotes BMSCs Osteoblastic Differentiation and Relieves Inflammation by Suppressing the NF-κB Pathways. *Stem Cells Int* 2023; **2023**: 7638842 [PMID: 37274021 DOI: 10.1155/2023/7638842]

33 **Tang Y**, Xie H, Chen J, Geng L, Chen H, Li X, Hou Y, Lu L, Shi S, Zeng X, Sun L. Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. *Stem Cells Dev* 2013; **22**: 668-678 [PMID: 22897816 DOI: 10.1089/scd.2012.0226]

34 **Kim K**, Kim JH, Kim I, Seong S, Kim N. TRIM38 regulates NF-κB activation through TAB2 degradation in osteoclast and osteoblast differentiation. *Bone* 2018; **113**: 17-28 [PMID: 29753717 DOI: 10.1016/j.bone.2018.05.009]

35 **Wang R**, Luo H, Yang D, Yu B, Guo J, Shao L, Okamura H, Qiu L. Osteoblast Jmjd3 regulates osteoclastogenesis via EphB4 and RANKL signalling. *Oral Dis* 2023; **29**: 1613-1621 [PMID: 35181970 DOI: 10.1111/odi.14160]

36 **Zhang B**, Zhang J, Liu G, Guo X, Liu X, Chen J. KDM3A Inhibition Ameliorates Hyperglycemia-Mediated Myocardial Injury by Epigenetic Modulation of Nuclear Factor Kappa-B/P65. *Front Cardiovasc Med* 2022; **9**: 870999 [PMID: 35571189 DOI: 10.3389/fcvm.2022.870999]

37 **Zhang BF**, Jiang H, Chen J, Guo X, Hu Q, Yang S. KDM3A inhibition attenuates high concentration insulin‑induced vascular smooth muscle cell injury by suppressing MAPK/NF‑κB pathways. *Int J Mol Med* 2018; **41**: 1265-1274 [PMID: 29286083 DOI: 10.3892/ijmm.2017.3351]

**Footnotes**

**Institutional review board statement:** This study was approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated with Capital Medical University.

**Institutional animal care and use committee statement:** The animal experiments were approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated with Capital Medical University.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 5, 2023

**First decision:** December 5, 2023

**Article in press:** January 17, 2024

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B




Grade C (Good): 0

Grade D (Fair): 0




Grade E (Poor): 0

**P-Reviewer:** Mostafavinia A, Iran **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Zhao S

**Figure Legends**



**Figure 1 Osteogenic and adipogenic differentiation of bone mesenchymal stem cells.** A: Bone mesenchymal stem cells (BMSCs) were isolated from mice bone marrow tissues. Flow cytometry was used to detect the expressions of CD29, CD31, CD90, CD45, CD34, MHCII, SCA-1 and CD11b; B-D: BMSCs were induced towards osteogenic differentiation. ALP staining was used to evaluate alkaline phosphatase (ALP) activity (B); calcium deposits were visualized by Alizarin red staining (C); the mRNA levels of osteogenic genes, including Osteocalin, Runt-related transcription factor 2 and ALP, were detected by reverse transcription coupled to the quantitative polymerase chain reaction (RT-PCR) (D); E and F: BMSCs were induced towards adipogenic differentiation. Representative images of Oil red O staining (E), the mRNA levels of adipogenic genes, such as peroxisome proliferator-activated receptor gamma and CCAAT enhancer-binding protein alpha, were measured by RT-PCR (F). All values are shown as mean ± SD. d*P* < 0.0001. *n* = 3. BMSC: Bone mesenchymal stem cell; ALP: Alkaline phosphatase; RunX2: Runt-related transcription factor 2; CEBPα: CCAAT enhancer-binding protein alpha; PPARγ: Peroxisome proliferator-activated receptor gamma.



**Figure 2 Jumonji domain-containing 1C was upregulated while** **nuclear factor-κB activation were not affected during bone mesenchymal stem cells osteogenic differentiation.** A: Jumonji domain-containing 1C (JMJD1C) mRNA level in bone mesenchymal stem cells after osteoblast induction was measured by reverse transcription coupled to the quantitative polymerase chain reaction; B-D: The protein expressions of JMJD1C and p-nuclear factor-κB were determined by western blot; E-G: The levels of inflammatory cytokines [interleukin (IL)-1β, IL-6 and tumor necrosis factor alpha] were detected using enzyme-linked immunosorbent assay. All values are shown as mean ± SD. a*P* < 0.05, d*P* < 0.0001, ns: No significance. *n* = 3. JMJD1C: Jumonji domain-containing 1C; TNF-α: Tumor necrosis factor alpha; IL: Interleukin; NF-κB: nuclear factor-κB.

**20240116 Figure 3**

**Figure 3 Jumonji domain-containing 1C knockdown inhibited osteogenic differentiation and upregulated p-nuclear factor-κB expression in bone mesenchymal stem cells.** Bone mesenchymal stem cells (BMSCs) were transfected with sh-NC or short hairpin RNA against Jumonji domain-containing 1C (sh-JMJD1C). A-C: Western blot was adopted to measure JMJD1C and p-nuclear factor-κB protein levels; D and E: Detection of osteogenic differentiation ability of BMSCs using alizarin red staining; F-H: Cytokines secretion level of interleukin (IL)-1β, IL-6 and tumor necrosis factor alpha were detected by enzyme-linked immunosorbent assay. All values are shown as mean ± SD. b*P* < 0.01, c*P* < 0.001, d*P* < 0.0001, *n* = 3. JMJD1C: Jumonji domain-containing 1C; TNF-α: Tumor necrosis factor alpha; IL: Interleukin; NF-κB: nuclear factor-κB.

**20240116 Figure 4**

**Figure 4 Jumonji domain-containing 1C was downregulated after bone marrow-derived macrophages osteoclast differentiation.** Bone marrow-derived macrophages were incubated with RANKL for osteoclast differentiation. A: Representative images of tissue-resistant acid phosphatase staining were presented; B-D: Jumonji domain-containing 1C mRNA and protein levels in MMCs after osteoclast induction were measured by reverse transcription coupled to the quantitative polymerase chain reaction and western blot. All values are shown as mean ± SD. a*P* < 0.05, d*P* < 0.0001, *n* = 3. JMJD1C: Jumonji domain-containing 1C.

**Table 1 The primer sequences used in reverse transcription coupled to the quantitative polymerase chain reaction**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Species** | **Direction** | **Sequence** | **Tm** | **Product lengths** | **Accession** |
| RunX2 | Mouse | Forward primer | AGAGTCAGATTACAGATCCCAGG | 60.12 | 109 bp | 90-112 |
| Reverse primer | TGGCTCTTCTTACTGAGAGAGG | 59.66 | 198-178 |
| Osteocalin | Mouse | Forward primer | CTGACCTCACAGATCCCAAGC | 61.54 | 114 bp | 66-85 |
| Reverse primer | TGGTCTGATAGCTCGTCACAAG | 59 | 179-160 |
| ALP | Mouse | Forward primer | CCAACTCTTTTGTGCCAGAGA | 60.2 | 110 bp | 44-64 |
| Reverse primer | GGCTACATTGGTGTTGAGCTTTT | 61.5 | 153-131 |
| PPAR-γ | Mouse | Forward primer | GGAAGACCACTCGCATTCCTT | 62.1 | 121 bp | 69-89 |
| Reverse primer | GTAATCAGCAACCATTGGGTCA | 60.6 | 189-168 |
| CEBP-α | Mouse | Forward primer | GCGGGAACGCAACAACATC | 61.2 | 124 bp | 840-860 |
| Reverse primer | GTCACTGGTCAACTCCAGCAC | 62.9 | 963-943 |
| JMJD1C | Mouse | Forward primer | ACATCACGGCGAAGGTCTC | 60.4 | 87 bp | 872-893 |
| Reverse primer | TGGGACTATTTGCTTGAGCAC | 61.5 | 958-938 |
| IL-1β | Mouse | Forward primer | GGTGCTGATGTACCAGTT | 60.5 | 95 bp | 66-86 |
| Reverse primer | TCTATACCACTTCACAAGTCGGA | 61.0 | 186-165 |
| IL-6 | Mouse | Forward primer | GAATTGCCATTGCACAACTCTTT | 60.9 | 105 bp | 642-662 |
| Reverse primer | GTCACTGGTCAACTCCAGCAC | 61.3 | 765-746 |
| TNF-α | Mouse | Forward primer | GAACCTTTCTGGCCCGTGT | 60.8 | 93 bp | 770-791 |
| Reverse prime | AGAAATCGCAATTCATGTCGCA | 61.2 | 856-336 |
| GAPDH | Mouse | Forward primer | GACGTGCCGCCTGGAGA | 62.5 | 95 bp | 8-28 |
| Reverse prime | GAAGAGTGGGAGTTGCTGTTGAA | 62.5 | 102-84 |

RunX2: Runt-related transcription factor 2; ALP: Alkaline phosphatase; PPARγ: Peroxisome proliferator-activated receptor gamma; CEBPα: CCAAT enhancer-binding protein alpha; JMJD1C: Jumonji domain-containing 1C; TNF-α: Tumor necrosis factor alpha; IL: Interleukin; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**